Bladder Cancer, Version 3.2024
Thomas W. Flaig, Philippe E. Spiess, Michael Abern et al. · Journal of the National Comprehensive Cancer Network · 2024
Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non-muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)-unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Cited by 273 works. doi:10.6004/jnccn.2024.0024
Authors
- Thomas W. Flaig
- Philippe E. Spiess
- Michael Abern
- Neeraj Agarwal
- Rick Bangs
- Mark K. Buyyounouski
- Kevin Chan
- Sam S. Chang
- Paul J. Chang
- Terence W. Friedlander
- Richard Evan Greenberg
- Khurshid A. Guru
- Harry W. Herr
- Jean H. Hoffman-Censits
- Hristos Z. Kaimakliotis
- Amar Upadhyaya Kishan
- SHILAJIT D. KUNDU
- Subodh M. Lele
- Ronac Mamtani
- Omar Y. Mian
References
- Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
- Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
- Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials
- The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials